Napabucasin

Manufactured by Merck Group

Sourced in United States

Napabucasin is a lab equipment product manufactured by the Merck Group. It is a chemical compound used as a research tool in scientific experiments and investigations. Napabucasin's core function is to serve as a chemical reagent for various laboratory procedures and analyses.

Automatically generated - may contain errors

Lab products found in correlation

Panobinostat, by Selleck Chemicals (1 mentions) Panobinostat, by Merck Group (1 mentions) Navitoclax, by Chemietek (1 mentions) Quisinostat, by Selleck Chemicals (1 mentions) Mannitol, by Merck Group (1 mentions) Navitoclax, by Thermo Fisher Scientific (1 mentions) A 1331852, by Chemietek (1 mentions) Phosal 50 pg, by Lipoid (1 mentions) Napabucasin, by Selleck Chemicals (1 mentions) Peg300, by Merck Group (1 mentions) Hydroxypropyl β cyclodextrin, by Merck Group (1 mentions) Peg400, by Merck Group (1 mentions) Tween 80, by Merck Group (1 mentions) Erlotinib, by Selleck Chemicals (1 mentions)

2 protocols using napabucasin

Drug Formulation and Preparation Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Napabucasin, panobinostat, and quisinostat were purchased from Selleckchem and A1331852 and Navitoclax from Chemietek, diluted in DMSO to make stock solutions, aliquoted and stored at −80C. Napabucasin was formulated by heating to 50C for 10 minutes and then sequentially adding 45% PEG300 (Sigma), 5% Tween80 (Sigma) and 45% sterile water, with vortexing after adding each component (Selleckchem). panobinostat was formulated by sequentially adding 48% PEG300 (Sigma), 2% Tween80 (Sigma) and 48% sterile water, with vortexing after adding each component (Selleckchem). quisinostat was formulated in 10% hydroxypropyl-b-cyclodextrin (Sigma), 25 mg/ml mannitol (Sigma), in sterile water(45 (link)). A1331852 was formulated by sequentially adding 10% Ethanol (Fisher), 60% Phosal 50 PG (Lipoid), and 30% PEG400 (Sigma), and vortexing (MedChemExpress). Navitoclax was formulated in 10% ethanol (Fisher), 30% PEG400 (Sigma), and 60% Phosal 50 PG (Lipoid), with vortexing after adding each component (MedChemExpress). Sorafenib was formulated in 90% corn oil (Selleckchem) with vortexing (MedChemExpress). Working solutions were made fresh prior to administration.

Lalazar G., Requena D., Ramos-Espiritu L., Ng D., Bhola P.D., de Jong Y.P., Wang R., Narayan N.J., Shebl B., Levin S., Michalidis E., Kabbani M., Vercauteren K.O., Hurley A.M., Farber B.A., Hammond W.J., Saltsman JA I.I.I., Weinberg E.M., Glickman J.F., Lyons B.A., Ellison J., Schadde E., Hertl M., Leiting J.L., Truty M.J., Smoot R.L., Tierney F., Kato T., Wendel H.G., LaQuaglia M.P., Rice C.M., Letai A., Coffino P., Torbenson M.S., Ortiz M.V, & Simon S.M. (2021). Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening. Cancer discovery, 11(10), 2544-2563.

+ Open protocol

+ Expand

Synthesis and Characterization of L61H46

Check if the same lab product or an alternative is used in the 5 most similar protocols

Napabucasin (BBI608) was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Erlotinib was purchased from Selleck Chemicals (Houston, TX, USA). L61H46 (Figure 1A), a MAC, was synthesized in our laboratory. The synthesis procedure was the same as our previous reports.25 (link) The compound L61H46 was recrystallized from CH₂Cl₂/CH₃CH₂OH, with a purity of 98.85% as determined by high performance liquid chromatography.

Bai E., Yang L., Xiang Y., Hu W., Li C., Lin J., Dai X., Liang G., Jin R, & Zhao C. (2018). L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway. Cancer Management and Research, 10, 565-581.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!